Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Non-Pegylated Lyposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone and Rituximab (R-COMP) as Initial Treatment for Patients with Splenic Marginal Zone Lymphoma (SMZL). A GISL Study

Emilio Iannitto, MD, Stefano Luminari, MD, Caterina Mammi, MD, Viviana Minardi, Francesco Merli, MD, Francesco Angrilli, MD, Caterina Stelitano, MD, Marina Cesaretti, Giovanni Franco, MD, Angelo M. Carella, MD, Massimo Federico, MD

Blood (2007) 110 (11): 1293.

https://doi.org/10.1182/blood.V110.11.1293.1293

Published: 2007

Journal Articles

Pre-Emptive Treatment with Cidofovir for Cytomegalovirus Antigenemia in Autologous Bone Marrow Recipient and CLL Patients on Therapy with Alemtuzumab.

Emilio Iannitto, MD, Viviana Minardi, MD, Antonino Mulè, MD, Renato Scalone, MD, Giuseppina Calvaruso, MD, Alessandra Crescimanno, MD, Concetta Lo Biundo, MD, Eliana Liardo, MD, Vincenzo Abbadessa, MD, Maurizio Musso, MD, Serenella Arista, MD

Blood (2006) 108 (11): 5286.

https://doi.org/10.1182/blood.V108.11.5286.5286

Published: 2006

Journal Articles

Response-Based Chemotherapy and Involved Field Radiation for Intermediate Stage Hodgkin Disease. A GISL/NHLSG Trial.

Emilio Iannitto, MD, Viviana Minardi, MD, Paolo G. Gobbi, MD, Giuseppina Calvaruso, MD, Caterina Stelitano, MD, Luca Baldini, MD, Francesco Merli, MD, Mario Petrini, MD, Luigi Marcheselli, Ph.D, Caterina Mammi, Ph.D, Stefano De Cantis, MD, Vincenzo Abbadessa, MD, Massimo Federico, MD

Blood (2006) 108 (11): 2475.

https://doi.org/10.1182/blood.V108.11.2475.2475

Published: 2006

Journal Articles

Splenic marginal zone lymphoma: a prognostic model for clinical use

Blood (2006) 107 (12): 4643–4649.

https://doi.org/10.1182/blood-2005-11-4659

Published: 2006

Journal Articles

Hepatitis B Virus Reactivation and Alemtuzumab Therapy.

Emilio Iannitto, MD, Viviana Minardi, MD, Giuseppina Calvaruso, MD, Antonino Mulè, MD, Donatella Ferraro, PhD, Emanuele Ammatuna, MD, Antonio Craxì, MD, Vincenzo Abbadessa, MD, Rosellina Di Stefano

Blood (2004) 104 (11): 4816.

https://doi.org/10.1182/blood.V104.11.4816.4816

Published: 2004

Journal Articles

Assessment of the Frequency of Additional Malignancies in Patients with Splenic Marginal Zone Lymphoma (SMZL).

Emilio Iannitto, MD, Stefano De Cantis, PhD, Viviana Minardi, MD, Vincenzo Callea, MD, Giuseppina Calvaruso, MD, Antonino Mulè, MD, Emanuele Ammatuna, MD, Caterina Stelitano, MD, Claudio Tripodo, MD, Achille Ambrosetti, MD, Giovanni Pizzolo, MD, Ada Florena, MD, Vito Franco, MD, Ada Florena, MD

Blood (2004) 104 (11): 4536.

https://doi.org/10.1182/blood.V104.11.4536.4536

Published: 2004

NARROW

Non-Pegylated Lyposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone and Rituximab (R-COMP) as Initial Treatment for Patients with Splenic Marginal Zone Lymphoma (SMZL). A GISL Study

Pre-Emptive Treatment with Cidofovir for Cytomegalovirus Antigenemia in Autologous Bone Marrow Recipient and CLL Patients on Therapy with Alemtuzumab.

Response-Based Chemotherapy and Involved Field Radiation for Intermediate Stage Hodgkin Disease. A GISL/NHLSG Trial.

Splenic marginal zone lymphoma: a prognostic model for clinical use

Hepatitis B Virus Reactivation and Alemtuzumab Therapy.

Assessment of the Frequency of Additional Malignancies in Patients with Splenic Marginal Zone Lymphoma (SMZL).

Email alerts

ASH Publications

American Society of Hematology

Non-Pegylated Lyposomal Doxorubicin, Cyclophosphamide, Vincristine, Prednisone and Rituximab (R-COMP) as Initial Treatment for Patients with Splenic Marginal Zone Lymphoma (SMZL). A GISL Study

Pre-Emptive Treatment with Cidofovir for Cytomegalovirus Antigenemia in Autologous Bone Marrow Recipient and CLL Patients on Therapy with Alemtuzumab.

Response-Based Chemotherapy and Involved Field Radiation for Intermediate Stage Hodgkin Disease. A GISL/NHLSG Trial.

Splenic marginal zone lymphoma: a prognostic model for clinical use

Hepatitis B Virus Reactivation and Alemtuzumab Therapy.

Assessment of the Frequency of Additional Malignancies in Patients with Splenic Marginal Zone Lymphoma (SMZL).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only